These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 16800841)

  • 1. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
    Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
    Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
    Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
    Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
    Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
    Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
    Dincaslan HU; Yavuz G; Unal E; Tacyildiz N; Ikinciogullari A; Dogu F; Guloglu D; Yuksek N; Ertem U
    Pediatr Hematol Oncol; 2010 Oct; 27(7):503-16. PubMed ID: 20677920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
    Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
    Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
    Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
    Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
    Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
    Graf M; Reif S; Hecht K; Kroell T; Nuessler V; Schmetzer H
    Eur J Haematol; 2005 Dec; 75(6):477-84. PubMed ID: 16313259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The single cell gel electrophoresis: a potential tool for DNA analysis of the patients with hematological malignancies.
    Bacová G; Gábelová A; Babusíková O; Slamenová D
    Neoplasma; 1998; 45(6):349-59. PubMed ID: 10210107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
    Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiphospholipid antibodies: their prevalence, clinical significance and correlation with cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma].
    Sciarra A; Stasi R; Stipa E; Masi M; Oliva F; Olivieri M; Perrotti A; Zaccari G; Amadori S; Papa G
    Recenti Prog Med; 1995 Feb; 86(2):57-62. PubMed ID: 7754173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome.
    Salih HR; Nuessler V; Denzlinger C; Starling GC; Kiener PA; Schmetzer HM
    Leuk Lymphoma; 2004 Feb; 45(2):301-8. PubMed ID: 15101715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
    Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
    Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Hock BD; McKenzie JL; Patton WN; Haring LF; Yang Y; Shen Y; Estey EH; Albitar M
    Cancer; 2003 Oct; 98(8):1681-8. PubMed ID: 14534885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.
    de Bont ES; Fidler V; Meeuwsen T; Scherpen F; Hählen K; Kamps WA
    Clin Cancer Res; 2002 Sep; 8(9):2856-61. PubMed ID: 12231527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma.
    Stasi R; Stipa E; Masi M; Oliva F; Sciarra A; Perrotti A; Zaccari G; Papa G
    Thromb Haemost; 1993 Oct; 70(4):568-72. PubMed ID: 8115979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
    Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
    Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.